Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002297 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
A Phase 3 study of Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, sponsored by BeiGene.
- Active
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT04002297 is a Phase 3 study of Mantle Cell Lymphoma; Non-Hodgkin Lymphoma that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 510 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04002297, a Phase 3 study of Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Conditions Studied
Interventions
- DRUG rituximab
- DRUG bendamustine
- DRUG zanubrutinib
Study Locations (20)
New South Wales
- Concord Repatriation General Hospital - Concord
- The Tweed Valley Hospital - Cudgen
- Saint Vincents Hospital Sydney - Darlinghurst
- Gosford Hospital - Gosford
- Calvary Mater Newcastle - Waratah
New York
- Icahn School of Medicine At Mount Sinai - New York
- Clinical Research Alliance, Inc - Westbury
Texas
- The University of Texas Md Anderson Cancer Center - Houston
- Joe Arrington Cancer Research and Treatment Center - Lubbock
Queensland
- Sunshine Coast Hospital and Health Service - Birtinya
- Icon Cancer Foundation - South Brisbane
California
- Chao Family Comprehensive Cancer Center - Orange
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Beth Israel Deaconess Medical Center (Bidmc) - Boston
Michigan
- University of Michigan Health System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04002297
The ClinicalTrials.gov registry entry for NCT04002297 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mantle Cell Lymphoma; Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which rituximab is the first listed.
NCT04002297 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New South Wales, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04002297 about?
NCT04002297 is a clinical study titled "A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation". This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
What is the current status of trial NCT04002297?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2019-08-20. Estimated completion is 2027-12.
What conditions does trial NCT04002297 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT04002297?
The interventions under investigation include: rituximab (DRUG), bendamustine (DRUG), zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT04002297?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04002297 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.